Pharmacom Biovet Net Income
| PHMB Stock | USD 0.0001 0.00 0.000003% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pharmacom Biovet, as well as the relationship between them.
Pharmacom Biovet's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pharmacom Biovet's valuation are provided below:Market Capitalization 1.1 M |
| Last Reported | Projected for Next Year | ||
| Net Loss | -639.6 K | -671.6 K | |
| Net Loss | -639.6 K | -671.6 K | |
| Net Loss | -639.6 K | -671.6 K |
Pharmacom | Net Income | Build AI portfolio with Pharmacom Stock |
Analyzing Pharmacom Biovet's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Pharmacom Biovet's current valuation and future prospects.
Latest Pharmacom Biovet's Net Income Growth Pattern
Below is the plot of the Net Income of Pharmacom Biovet over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pharmacom Biovet financial statement analysis. It represents the amount of money remaining after all of Pharmacom Biovet operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pharmacom Biovet's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharmacom Biovet's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (556.18 K) | 10 Years Trend |
|
Net Income |
| Timeline |
Pharmacom Net Income Regression Statistics
| Arithmetic Mean | (1,604,451) | |
| Coefficient Of Variation | (266.20) | |
| Mean Deviation | 1,949,823 | |
| Median | (556,180) | |
| Standard Deviation | 4,271,022 | |
| Sample Variance | 18.2T | |
| Range | 17.6M | |
| R-Value | 0.40 | |
| Mean Square Error | 16.3T | |
| R-Squared | 0.16 | |
| Significance | 0.11 | |
| Slope | 341,831 | |
| Total Sum of Squares | 291.9T |
Pharmacom Net Income History
Other Fundumenentals of Pharmacom Biovet
Pharmacom Biovet Net Income component correlations
Click cells to compare fundamentals
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. Anticipated expansion of Pharmacom directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pharmacom Biovet assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Pharmacom Biovet's market price often diverges from its book value, the accounting figure shown on Pharmacom's balance sheet. Smart investors calculate Pharmacom Biovet's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Pharmacom Biovet's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Pharmacom Biovet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pharmacom Biovet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pharmacom Biovet 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pharmacom Biovet's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pharmacom Biovet.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Pharmacom Biovet on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Pharmacom Biovet or generate 0.0% return on investment in Pharmacom Biovet over 90 days. Pharmacom Biovet is related to or competes with Mid-Atlantic Home, Cyduct Diagnostics, DATATRAK International, Escalon Medical, and Ligand Pharmaceuticals. PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States More
Pharmacom Biovet Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pharmacom Biovet's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pharmacom Biovet upside and downside potential and time the market with a certain degree of confidence.
Pharmacom Biovet Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmacom Biovet's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pharmacom Biovet's standard deviation. In reality, there are many statistical measures that can use Pharmacom Biovet historical prices to predict the future Pharmacom Biovet's volatility.Pharmacom Biovet Backtested Returns
We have found three technical indicators for Pharmacom Biovet, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Pharmacom Biovet are completely uncorrelated.
Auto-correlation | 0.93 |
Excellent predictability
Pharmacom Biovet has excellent predictability. Overlapping area represents the amount of predictability between Pharmacom Biovet time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pharmacom Biovet price movement. The serial correlation of 0.93 indicates that approximately 93.0% of current Pharmacom Biovet price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.93 | |
| Spearman Rank Test | 0.63 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pharmacom Operating Income
Operating Income |
|
Based on the recorded statements, Pharmacom Biovet reported net income of (556,180). This is 100.16% lower than that of the Health Care Providers & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.1% higher than that of the company.
Pharmacom Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmacom Biovet's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharmacom Biovet could also be used in its relative valuation, which is a method of valuing Pharmacom Biovet by comparing valuation metrics of similar companies.Pharmacom Biovet is currently under evaluation in net income category among its peers.
Pharmacom Fundamentals
| Current Valuation | 1.08 M | ||||
| Net Income | (556.18 K) | ||||
| Total Debt | 61.54 K | ||||
| Beta | 168.8 | ||||
| Market Capitalization | 1.08 M | ||||
| Total Asset | 112.36 K | ||||
| Retained Earnings | (19.05 M) | ||||
| Working Capital | (29 K) | ||||
| Current Liabilities | 29 K | ||||
| Net Asset | 112.36 K |
About Pharmacom Biovet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmacom Biovet's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmacom Biovet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmacom Biovet based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pharmacom Biovet offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pharmacom Biovet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacom Biovet Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacom Biovet Stock:Check out For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. Anticipated expansion of Pharmacom directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pharmacom Biovet assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Pharmacom Biovet's market price often diverges from its book value, the accounting figure shown on Pharmacom's balance sheet. Smart investors calculate Pharmacom Biovet's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Pharmacom Biovet's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Pharmacom Biovet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pharmacom Biovet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.